New treatment for epidermolysis bullosa and fibrosis

Summary of the technology

CSIC, Carlos III University of Madrid and CIEMAT have repositioned drugs that stimulate endogline
expression and modulate the TGF-β route for a new clinical use in the treatment of fibrosis, such as
epidermolysis bullosa (EB). EB includes a heterogeneous group of rare hereditary diseases of the skin in
which in its infantile incidence the patients are known as "butterfly children". It is a new therapy for a
rare pathology, with potential in a wide spectrum of fibrosis, which would improve the possibilities of
treatment of patients, improving their quality of life.

Industrial partners from the pharmaceutical industry are being sought for its development in a wide
variety of fibrotic pathologies through a patent licence agreement.

An offer for Patent Licensing

CSIC - Consejo Superior de Investigaciones Científicas

Drug Repositioning

Epidermolysis bullosa (EB) comprises a clinically and genetically heterogeneous group of rare skin diseases characterized by the formation of skin blisters, spontaneous or induced by minimal trauma. In the development of EB pathogenesis there may be a connection between collagen VII deficit and an exacerbated bioavailability and overexpression of TGF-β1. It has been seen that overproduction of the ligand TGF-β1, can be counteracted by drugs that cause an increase in endogline levels.
Researchers have identified the widely used drugs, raloxifene and N- acetylcysteine, that produce an increase in the protein levels of endogline and a decrease in TGF-β1, protein levels in fibroblasts from EB patients.
Therefore, both drugs are postulated as potentially useful orphan drugs for the treatment of EB.

Main innovations and advantages

· Safety, effective and selective repositioned drugs are proposed for thetreatment of epidermolysis bullosa (EB) which may lead to a clinicalbenefit including an increase in the quality of life of the patients withthis disease.
· The drugs can be used separately or in combination in differentpharmaceutical formulations.
· Their mechanism in the TGF-β1 route presents a potential for theclinical use in fibrosis and other related diseases associated with highphysiopathological levels of this growth factor.

Intellectual property status

  • Granted Patent
  • Patent application number :-

Related Keywords

  • Pharmaceutics
  • Biological Sciences
  • Medicine, Human Health
  • Medical Research
  • Pharmaceutical Products / Drugs
  • Protein Engineering
  • Genetic Engineering / Molecular Biology
  • Enzymology/Protein Engineering/Fermentation
  • Medical Health related
  • Therapeutic
  • Other Medical/Health Related
  • Clinical Medicine
  • fibrosis
  • skin diseases
  • epidermolysis bullosa

About CSIC - Consejo Superior de Investigaciones Científicas

The Spanish National Research Council (in Spanish 'Consejo Superior de Investigaciones Científicas (CSIC)') is a government agency for basic and applied scientific research.

It is the largest public research organization in Spain, with presence in all the Autonomous Communities through 126 centers and 145 associated units.

CSIC - Consejo Superior de Investigaciones Científicas

Never miss an update from CSIC - Consejo Superior de Investigaciones Científicas

Create your free account to connect with CSIC - Consejo Superior de Investigaciones Científicas and thousands of other innovative organizations and professionals worldwide

CSIC - Consejo Superior de Investigaciones Científicas

Send a request for information
to CSIC - Consejo Superior de Investigaciones Científicas

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support